Jinyu Bio-Technology News

Jinyu Bio-Technology (600201.SH): Currently, the domestic meat product market has not fully recovered, and the prices of meat, eggs, and milk are at a low point.

On March 20, Gelonghui reported that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the domestic meat product market consumption has not fully recovered yet, with the prices of meat, eggs, and milk at a low point, and downstream customers are still under pressure regarding cash flow, resulting in overall pressure on the Animal Protection Industry. The company leverages its solid R&D foundation and years of experience in the industry, forming differentiated competition through product iteration at the R&D level to succeed in a fiercely competitive market environment.

Gelonghui FinanceMar 20 16:37

Jinyu Bio-Technology (600201.SH): A total of 3.2858 million shares of the company have been repurchased.

On March 3, Gelonghui reported that Jinyu Bio-Technology (600201.SH) announced that, as of February 28, 2025, the company had repurchased 3.2858 million shares through the centralized bidding system of the Shanghai Exchange, accounting for 0.2933% of the company's total share capital, with the highest transaction price being 6.54 yuan/share, the lowest transaction price being 6.37 yuan/share, and the total amount paid being 21.1236 million yuan (excluding commission, transfer fees, and other transaction costs).

Gelonghui FinanceMar 3 17:17

Express News | Jinyu Bio-Technology: Subsidiary Jinyu Baoling has obtained the new veterinary drug registration certificate for bovine mycoplasma live vaccine.

BreakingsFeb 27 16:53

Jinyu Bio-technology Announces New Veterinary Drug Registration

MT NewswiresFeb 19 18:19

Jinyu Bio-Technology (600201.SH): Exploring the application of deepseek in the field of Biological Vaccine research and development.

Gelonghui reported on February 18 that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company is currently collaborating with top Universities and research institutes in China, extensively using AI in vaccine development for tasks such as antigen screening and sequence optimization. In the future, AI will continue to be deeply utilized for target selection, process optimization, vaccine design, high-dimensional evaluation, and exploring the application of deepseek in the field of Biological Vaccine research and development.

Gelonghui FinanceFeb 18 18:40

Jinyu Bio-Technology (600201.SH): The Brucella gene deletion live vaccine (RM6 strain, rough type) has obtained a new veterinary drug registration certificate.

Jinyu bio-technology (600201.SH) issued an announcement, according to the national "Regulations on Veterinary Drugs" and "Veterinary Drug Registration Measures" ...

Zhitong FinanceFeb 17 17:02

Express News | Jinyu Bio-Technology: Subsidiary obtains new veterinary drug registration certificate.

BreakingsFeb 17 16:50

Jinyu Bio-Technology (600201.SH): Repurchased 0.22 million shares for the first time.

Gelonghui, on January 22, announced that Jinyu Bio-Technology (600201.SH) has repurchased a total of 220,000 shares through centralized bidding, accounting for 0.0196% of the company's total share capital. The highest transaction price was 6.46 yuan/share, the lowest transaction price was 6.44 yuan/share, and the total amount paid was 1,419,600 yuan (excluding commission, transfer fees, and other transaction costs).

Gelonghui FinanceJan 22 17:15

Jinyu Biotechnology Co., Ltd. 2024 Annual Performance Forecast

SZSIJan 18 00:00 · Announcements

Jinyu Bio-Technology (600201.SH): The net profit is expected to decrease by 56.61% to 63.43% in 2024.

Gelonghui, January 17 | Jinyu Bio-Technology (600201.SH) announced its performance forecast for 2024, expecting a net income attributable to shareholders of the listed company to be between 103.72 million yuan and 123.08 million yuan, a year-on-year decrease of 56.61% to 63.43%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 48.4 million yuan and 67.76 million yuan, a year-on-year decrease of 73.37% to 80.98%. In 2024, impacted by the cyclicality of the breeding industry and capacity reduction, along with clients' demand for cost reduction, the animal protection industry.

Gelonghui FinanceJan 17 22:16

Jinyu Bio-Technology (600201.SH): Collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform.

On December 27, Gelonghui reported that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company has collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform. This effort aims to position themselves early in the fourth generation vaccine—digital vaccines, gradually establishing a complete system from database construction, AI computing power, vaccine design, animal testing validation, to vaccine registration and industrialization. On one hand, AI deep learning models will be utilized to enhance the development and application of animal health products, while on the other hand, the animal health industry’s large-scale data generation capability will be leveraged to continuously optimize AI large models at various stages of vaccine research and development.

Gelonghui FinanceDec 27, 2024 17:38

CHINARES PHARMA (03320) subsidiary CHINARES PHARMA Holdings' Shareholding in China Resources Boya Bio-pharmaceutical Group has reached 1%.

CHINARES PHARMA (03320) announced that between November 8, 2024, and December 18, 2024, public...

Zhitong FinanceDec 18, 2024 22:36

Jinyu Bio-technology Gets China Approval for Cattle Infection Treatment

MT NewswiresDec 18, 2024 19:00

Express News | Jinyu Bio-Technology: A subsidiary has received the approval number for a live vaccine against Brucellosis.

BreakingsDec 17, 2024 15:52

Tianjin Ringpu Bio-Technology (300119.SZ) plans to change the company name to Tianjin Ringpu Bio-Technology Co., Ltd.

Tianjin Ringpu Bio-Technology (300119.SZ) announced that the company plans to change its Chinese name from “Tianjin Ringpu Bio-Technology Co., Ltd...”

Zhitong FinanceDec 13, 2024 20:05

Jinyu Bio-Technology (600201.SH): The business has not yet involved in the digital economy.

Gelonghui reported on December 13 that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company’s business has not yet involved the digital economy sector.

Gelonghui FinanceDec 13, 2024 18:11

Express News | Baolingbao Biology and Fengli Jingqiu have reached a strategic cooperation.

BreakingsDec 12, 2024 09:50

The subsidiary of jinyu bio-technology (600201.SH) has obtained a new veterinary drug registration certificate.

Jinyu bio-technology (600201.SH) issued an announcement, according to the national "Regulations on Veterinary Drugs" and "Veterinary Drug Registration Measures" ...

Zhitong FinanceDec 6, 2024 16:33

Express News | jinyu bio-technology: Subsidiary obtained new veterinary drug registration certificate for foot-and-mouth disease virus O-type, A-type bivalent virus-like particle vaccine.

BreakingsDec 6, 2024 16:30

Express News | Jinyu bio-technology: A subsidiary has obtained a new veterinary drug registration certificate.

BreakingsDec 6, 2024 16:29